Clinical trial · Interventional
London Investigation Into diElectric Scanning of Lesions
Performance Evaluation of the MARIA (Multi Static Array Processing of Radiowave Image Acquisition) Radar Breast Imaging System in Patients With Breast Cancer and in Patients Assessed in the Symptomatic Breast Clinic.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The MARIA breast imaging system is a novel CE-marked radio-frequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues. The performance and imaging characteristics of MARIA are not yet well demonstrated. The investigators aim to evaluate some aspects of this potentially important new technology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MARIA scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Breast cancer accuracy
- description
- Patients with a known or suspected (and subsequently proven) breast cancer
- interventionNames
- Diagnostic Test: MARIA scan
- type
- EXPERIMENTAL
- label
- Imaging characteristics and performance
- description
- Patients attending the symptomatic clinic
- interventionNames
- Diagnostic Test: MARIA scan
- type
- EXPERIMENTAL
- label
- Tumour response in neoadjuvant treatment
- description
- Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Attending a symptomatic breast care clinic OR Patients who have a diagnosed or suspected breast cancer (P5/M5/U5/B5). * Female sex * 18 years or older. * Able to provide informed consent. * Not in any identified, vulnerable group. Exclusion Criteria: * Unable to mount MARIA™ patient bed using provided 2-step * Unable to lie in the prone position * Patients who have undergone biopsy less than 5 days before the MARIA™ scan * Patients with implanted electronics. * Patients with breast implants. * Patients with nipple piercings (unless they are removed prior to the MARIA™ scan) * Breast sizes smaller than 197ml or greater than 1L in volume
References
Publications (2)
- BACKGROUNDPreece AW, Craddock I, Shere M, Jones L, Winton HL. MARIA M4: clinical evaluation of a prototype ultrawideband radar scanner for breast cancer detection. J Med Imaging (Bellingham). 2016 Jul;3(3):033502. doi: 10.1117/1.JMI.3.3.033502. Epub 2016 Jul 20. PMID 27446970
- BACKGROUNDSaadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ. 2015 Oct 6;351:h4901. doi: 10.1136/bmj.h4901. PMID 26442924